Preprodynorphin mediates locomotion and D-2 dopamine and mu-opioid receptor changes induced by chronic 'binge' cocaine administration by Bailey, A et al.
 1
Title:  Preprodynorphin mediates locomotion and D2 dopamine and - opioid receptor 
changes induced by chronic “binge” cocaine administration  
 
Authors: aA. Bailey, aJ.H. Yoo, bI. Racz, bA. Zimmer, aI. Kitchen.  
 aSchool of Biomedical and Molecular Sciences, University of Surrey, Guildford, UK 
bDepartment of Molecular Psychiatry, Life & Brain Center, University of Bonn, Bonn, 
Germany 
 
Corresponding author: Dr Alexis Bailey 
 School of Biomedical and Molecular Sciences 
University of Surrey 
Guildford 
Surrey 
GU2 7XH, UK 
 Tel: +44 (0)1483 689701, Fax:  +44 (0)1483686401; E.mail: a.bailey@surrey.ac.uk 
 
Number of figures: 7 
Number of tables: 0 
Number of pages: 42 
 
 
 
 
 
 
 
 2
 
Keywords: cocaine, preprodynorphin, knockout, sensitization, dopamine, opioid 
 
Abbreviated title: Chronic cocaine and ppDYN knockout mice 
 
Abstract 
 
Evidence suggests that the -opioid receptor (KOP-r) system plays an important role in 
cocaine addiction.  Indeed, cocaine induces endogenous KOP activity which is a mechanism 
that opposes alterations in behaviour and brain function resulting from repeated cocaine use.  
In this study, we have examined the influence of deletion of preprodynorphin (ppDYN) on 
cocaine-induced behavioural effects and on hypothalamic-pituitary-adrenal (HPA) axis 
activity.  Furthermore, we have measured -opioid receptor (MOP-r) agonist stimulated 
[35S]GTPS , dopamine D1, D2 receptor and dopamine transporter (DAT) binding.  Male wild-
type (WT) and ppDYN knockout (KO) mice were injected with saline or cocaine (45 
mg/kg/day), in a “binge” administration paradigm for 14 days.  Chronic cocaine produced an 
enhancement of locomotor sensitization in KO.  No genotype effect was found on stereotypy 
behaviour.  Cocaine enhanced MOP-r activation in WT but not in KO.  There was an overall 
decrease in D2 receptor binding in cocaine treated KO but not in WT mice.   No changes were 
observed in D1 and DAT binding.  Cocaine increased plasma corticosterone levels in WT but 
not in KO.  The data confirms that the endogenous KOP system inhibits dopamine 
neurotransmission and that ppDYN may mediate the enhancement of MOP-r activity and the 
activation of the HPA axis after chronic cocaine treatment. 
 
 
 3
Introduction 
 
Cocaine, one of the most commonly used psychostimulants, induces the elevation of 
extracellular dopamine in the striatum (Carboni et al. 1989; Maisonneuve et al. 1995; Wise 
1996) by blocking the dopamine transporter (DAT) (Heikkila et al. 1975).  There is increasing 
evidence that the - opioid receptor (KOP-r) agonists are able to modulate the neurochemical 
and behavioural effects of cocaine.  KOP-r agonists were shown to significantly decrease 
cocaine self-administration in rodents (Glick et al. 1995; Kuzmin et al. 1997b), to decrease 
cocaine-induced locomotor activity (Crawford et al. 1995; Zhang et al. 2004b), stereotypy 
(Heidbreder et al. 1993; Heidbreder et al. 1995), conditioned place preference (Crawford et al. 
1995; Zhang et al. 2004a; Zhang et al. 2004b) and the development of locomotor sensitization 
to cocaine (Shippenberg et al. 1996).   
 
There is a large body of evidence indicating that the -opioid system is affected by chronic 
cocaine treatment (Kreek et al. 2002).  An increase in preprodynorphin (ppDYN) (considered 
to be an endogenous KOP-r ligand) mRNA has been repeatedly observed in the caudate 
putamen of rodents after cocaine administration (Spangler et al. 1993; Turchan et al. 1998; 
Werme et al. 2000).  Together, these results suggest that cocaine induces endogenous KOP 
activity, which is a homeostatatic mechanism that opposes alterations in behaviour and 
neurochemistry resulting from repeated cocaine use.  To test this hypothesis, this study 
investigated the influence of deletion of the ppDYN gene on chronic “binge” cocaine-induced 
locomotion, stereotypy and sensitization. 
 
Moreover, there is evidence for an interaction of the KOP-r system with the dopaminergic and 
the -opioidergic systems.  Chronic repeated administration of selective KOP-r agonists were 
 4
shown to decrease DAT (Thompson et al. 2000; Collins et al. 2001b) as well as D2 dopamine 
receptor density (Izenwasser et al. 1998) and function (Izenwasser et al. 1998; Acri et al. 
2001) in the striatum of rats and to upregulate -opioid receptor (MOP-r) G- protein 
activation in mouse brain  (Narita et al. 2003).  Given that chronic cocaine administration also 
decreases D2 dopamine receptor density (Volkow et al. 1990; Volkow et al. 1993) and DAT 
(Sharpe et al. 1991; Pilotte et al. 1994; Pilotte et al. 1996) and upregulates MOP-r G protein 
activity in the striatum (Schroeder et al. 2003), it was hypothesized that the neuroadaptive 
changes in the dopaminergic and  -opioidergic systems occurring after chronic cocaine 
administration might be mediated by ppDYN.  To test this hypothesis, this study examined 
the influence of deletion of the ppDYN gene on cocaine-induced changes in these systems.   
 
Finally, as recent evidence clearly shows that antagonists of the KOP-r system or disruption 
of the ppDYN gene blocks stress-induced cocaine responses (McLaughlin et al. 2003), it was 
hypothesized that cocaine-induced activation of the hypothalamic-pituitary-adrenal (HPA) 
axis may subsequently activate the endogenous KOP-r system presumably modulating drug 
reward.  To test this hypothesis, this study examined the influence of deletion of the ppDYN 
gene on chronic “binge” cocaine induced activation of the HPA axis.  
 
Materials and Methods 
 
Generation of knockout mice and treatment 
 
The development of mice with a deletion of the ppDYN gene has been previously described 
(Zimmer et al. 2001).  All animals were crossed for at least 10 generations to C57BL/6J mice 
and were therefore congenic for this genetic background.  KO and WT mice from the same 
litters were bred from heterozygous mice and genotyped by PCR at weaning.  Male mice aged 
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between 9 and 16 weeks were used in this study.  Mice were individually housed in a 
temperature and humidity controlled room with a 12h light/dark schedule for at least 2 weeks 
before experiments.  Food and water were available at libitum. Following acclimatisation, 
three daily equal intraperitoneal (i.p.) injections of either saline (10 ml/kg) or cocaine (15 
mg/kg/injection giving a total of 45 mg/kg/day)  were then administered in a steady dose 
“binge” paradigm to mimic a common pattern of self-administration in human cocaine 
abusers (Kreek 1996).  The injections were given at 1 h intervals commencing 60 min 
following the daily light cycle.  All animals received a total of 14 days of “binge” pattern 
injections.  This paradigm has been extensively utilized in the cocaine addiction field to 
model one common pattern of human cocaine abuse, namely the abuser who binges on 
cocaine daily but only after work hours (Branch et al. 1992; Unterwald et al. 1992; Spangler 
et al. 1993; Unterwald et al. 1993; Maisonneuve and Kreek 1994; Unterwald et al. 1994b; 
Unterwald et al. 1994a; Maisonneuve et al. 1995; Unterwald et al. 1995; Spangler et al. 
1996a; Spangler et al. 1996b; Zhou et al. 1999; Zhang et al. 2002; Schlussman et al. 2003; 
Schroeder et al. 2003; Zhang et al. 2003; Bailey et al. 2005a; Bailey et al. 2005b; Schlussman 
et al. 2005; Zhou et al. 2006; Zhou et al. 2007).  All studies were performed in accordance 
with protocols approved by the German Animal Protection Law (issued in 1998) which were 
approved by the Bezirksregierung Köln. 
 
Cocaine-induced locomotor activity 
 
Horizontal ambulatory activity was measured in open field chambers (40cm length x 20 cm 
wide x 20 cm height).  Total activity, measured with a videotracking system (Videomot2, 
TSE Systems GmbH, Germany) was measured at 5 min intervals.  The protocol for locomotor 
testing was a slight modification of that  used by Heidbreder et al. (1998).  When mice were 
tested in the open field activity chambers, they were habituated for 30 min after which they 
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received an i.p. injection of saline or cocaine (15 mg/kg).  The animals were then returned 
immediately to the chambers where locomotor activity was assessed for 30 min.  The 
locomotor activity for each mouse after injection of the first of the three daily treatments of 
saline or cocaine was monitored daily for a period of 14 days.  From former published study 
which used an identical “binge” administration protocol (Schlussman et al. 2003) and in 
accordance with studies done in our laboratory using the same protocol (unpublished data), 
the locomotor activity of mice in response to cocaine does not change significantly after the 
second and third injection compared to the first. 
 
Cocaine-induced stereotypy 
 
One hour after each first injection of saline or cocaine, mice received a second i.p. injection of 
saline or cocaine (15 mg/kg), were placed immediately in their home cage, and videotaped 
twenty minutes later for 30 min.  Videotapes were later rated for stereotypy by a trained 
observer blind as to the animal’s treatment group.  The rating was based on a slight adaptation 
of the scale used by Schlussman et al., (2003) and consisted of a graded scale of drug induced 
behaviours: 1) asleep, inactive; 2) alert, actively grooming; 3) increased sniffing (occasional 
light sniffing, often while exploring the cage); 4) intermittent rearing and sniffing (two or 
three rears in a 20s period, with sniffing frequently at the apex of the rear); 5) increased 
locomotion; 6) intense sniffing in one location (rapid sniffing, often with head down is the 
predominant behaviour displayed); 7) continuous pivoting and sniffing (no rearing, no 
locomotion);  8) intermittent rearing and sniffing (intermittent up and down rearing behaviour 
with locomotion); 9) maintained rearing and sniffing (animal remains up on hind legs 
throughout most of the observed period); 10) splayed limbs.  Each animal received a single 
score following each injection, which corresponded to the specific stereotypic behaviour 
predominantly observed during the 30 sec observation period.  The stereotypy behaviour of 
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each mouse injected with the second of the three daily injections of saline or cocaine was 
scored every day for the 14 days duration of the study. 
 
D1, D2 dopamine receptor and dopamine transporter (DAT) autoradiography 
 
Animals were killed 30 min following the last injection of saline or cocaine on day 14 of the 
study and the brains were immediately removed, quickly frozen and stored at  
-80oC until sectioning.  Quantitative autoradiography was performed as detailed previously 
for D1 , D2 dopamine receptor binding (Lena et al. 2004) and DAT binding (Javitch et al. 
1985) using the general procedures of Kitchen et al. (1997).  Adjacent 20 m coronal sections 
were cut at a interval of 300 m from chronic “binge” saline or cocaine treated WT or 
ppDYN KO brains for the determination of total and non-specific binding of [3H]SCH-23390 
(containing 1 μM mianserin in order to block 5-HT2 and 5-HT1c receptor binding sites), 
[3H]raclopride and [3H]mazindol at D1, D2 dopamine receptor and DAT, respectively.  Ligand 
concentrations were 3-4 x Kd with all ligands used at a concentration of 4 nM.  Non-specific 
binding (NSB) was defined in the presence of cis-flupenthixol (10 M), sulpiride (10 M), or 
unlabelled mazindol (10 M) for [3H]SCH-23390,  [3H]raclopride and [3H]mazindol binding 
respectively.  Following binding for a period of 90 min, 60 min or 45 min for D1, D2 
dopamine receptor and DAT binding respectively, and washing in ice cold buffer (6x1 min 
for D1 and D2 dopamine receptor binding and 2x1 min for DAT binding), the slides were 
apposed to [3H]Hyperfilm (Amersham) for 4 weeks in the case of D1 and DAT binding and 3 
weeks for D2 binding.  Sections from chronic “binge” saline and cocaine treated WT and KO 
mice were processed together in a paired protocol.  Films were developed using 50% Kodak 
D19 developer.  Quantitative analysis of brain receptors was performed as detailed previously 
(Kitchen et al. 1997; Lena et al. 2004).  Using an MCID image analyser (Image Research, 
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Canada), brain structures were identified using the mouse brain atlas of Franklin and Paxinos 
(1997).  In detail the following structures were analysed by sampling 5-10 times with a box 
tool: cortex (8 x 8 mm) and olfactory tubercle (6 x 6 mm).  All the other areas were analysed 
by freehand drawing tool. 
 
-opioid receptor  (MOP-r) stimulated [35S]GTPS binding autoradiography 
 
General procedures for MOP-r agonist-stimulated guanosine 5’-[-[35S]thio]-triphosphate 
([35S]GTPS) autoradiography were performed essentially as described by Sim et al. (1996) 
and  Kirschke et al. (2002).  Adjacent 20 m coronal sections were cut at a interval of 300 m 
from chronic “binge” saline or cocaine treated WT or ppDYN KO brains for the 
determination of basal, DAMGO-stimulated [35S]GTPS and NSB.  Sections were 
preincubated in assay buffer (50 mM TrisHCl, 3 mM MgCl2.6H2O, 0.2 mM EGTA, 100 mM 
NaCl, pH 7.4 at 25 oC) for 10 min.  Sections were then incubated in assay buffer containing 1 
mM GDP, pH 7.4 at 25 oC for 15 min and rinsed in fresh assay buffer.  MOP-r agonist-
stimulated activity was determined by incubating the sections in [35S]GTPS (0.04 nM) with 
the selective -opioid receptor agonist DAMGO (5 M) for 2 h in assay buffer containing 1 
mM GDP.  Basal G protein activity was determined by incubating the sections in [35S]GTPS 
in the presence of GDP (1 mM) and in the absence of the agonist.  NSB was assessed by 
incubating sections with [35S]GTPS in assay buffer in the presence of 10 M unlabelled 
GTPS.  After incubation for 2 h, slides were rinsed twice for 3 min in ice cold buffer (50 mM 
TrisHCl, pH 7.4 at 0 oC) followed by one rinse in de-ionised water.  Slides were then dried for 
2 h in a cold air stream and drying was continued for a further 2 days using anhydrous 
calcium sulphate (Drierite, BDH Chemicals, Poole, UK).  Sections from chronic “binge” 
saline and cocaine treated WT and KO mice were apposed in a paired protocol to Kodak MR 
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film together with [14C] standards (Amersham) for 3 days.  Quantitative analysis of optical 
density was performed as detailed previously (Schroeder et al. 2003) using [14C] standards.  
For each brain region examined, agonist-stimulated activity was calculated by first subtracting 
the optical density of NSB sections from the optical density of both agonist-stimulated and 
basal binding sections.  
 
Measurement of corticosterone plasma levels 
 
Chronic  “binge” saline and cocaine treated WT and ppDYN KO mice were decapitated at the 
end of the treatment and trunk blood  from each animal was collected in tubes placed on ice, 
and was spun in a refrigerated centrifuge.  Plasma was separated and stored at -20oC for 
corticosterone measurements by radioimmunoassay. Corticosterone levels were assayed by 
using a rat/mouse corticosterone [125I] kit (MP Biomedicals, NY).  All corticosterione levels 
were determined in duplicate in a single assay. 
 
Statistics 
 
Cocaine-induced locomotor activity in 5 min bins was analysed by three-way analysis of 
variance (ANOVA) (for factors genotype, treatment and day) with repeated measures for day, 
followed by post hoc LSD test.  Values are expressed as mean ± S.E.M of total distance 
travelled per 5 min bin.  Stereotypy behaviour was analysed by daily mean ± S.E.M of 
stereotypy score measured 20 min after the second saline or cocaine injection.  The statistics 
approach used in this case was three-way ANOVA (for factors genotype, treatment and day) 
with repeated measures for day, followed by post hoc LSD test.  Since the expression of 
behavioural stereotypy was measured with a behavioural rating scale, non parametric Mann-
Whitney U tests were also used in order to confirm results obtained by the ANOVA.  Two-
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way ANOVA (for factors genotype and treatment) was used for comparison of quantitative 
measures of  D1, D2 receptors, DAT and- opioid receptor stimulated [35S]GTPS binding in 
chronic “binge” saline and cocaine treated WT and KO brains followed by post hoc LSD test.  
In order to compare quantitative measures of autoradiographic binding for D1, D2 receptors, 
DAT and- opioid receptor stimulated [35S]GTPS binding in each region of the brains of 
chronic “binge” saline and cocaine treated WT and KO animals, three-way ANOVA (for 
factors genotype, treatment and region) was used followed by post hoc LSD test.  Comparison 
of plasma corticosterone levels in chronic “binge” saline and cocaine treated WT and KO 
mice was performed using two-way ANOVA (for factors genotype and treatment) followed 
by post hoc LSD test. 
 
Materials  
 
Cocaine HCl was purchased from Sigma-Aldrich (Dorset, UK);  [3H]SCH-23390 (70 
Ci/mmol), [3H]raclopride (60.1 Ci/mmol) and [3H]mazindol (20.6 Ci/mmol) were purchased 
from Perkin Elmer (Bucks, UK); cis flupenthixol, sulpiride and mazindol were purchased 
from Sigma-Aldrich.  
 
Results 
 
Influence of ppDYN deletion on acute cocaine-induced locomotion and locomotor 
sensitization 
 
Basal locomotor activity of naïve WT and ppDYN KO mice was measured 15 min after 
placement in an open field for 15 min (data not shown).  Two-way ANOVA, for factors 
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genotype x time after placement in open field with repeated measures on the second variable, 
did not show any significant genotype or time effect (P>0.05).   
 
Locomotor activity of WT and KO mice was measured after the first injection of saline or 
cocaine (15 mg/kg) every day for the 14 day duration of the study.  For brevity, locomotor 
activity of the mice on day 1 (acute administration) (Fig. 1A), day 3, 7 and 14 (Fig. 1B-D) are 
presented.  Three-way ANOVA, for factors genotype (WT, KO), treatment (saline, cocaine) 
and day (days 1-14) with repeated measures on the last variable, showed a significant main 
effect of treatment [F(1,109)=285.94, P<0.0001], day [F(1,1391)=25.19, P<0.0001], and a 
significant treatment x genotype interaction [F(1,109)=3.93, P<0.05] and treatment x day 
interaction [F(1,1391)=22.9, P<0.0001].  Acute cocaine (15 mg/kg) injection significantly 
increased horizontal ambulatory activity of both WT and KO animals (P<0.0001 for WT and 
P<0.0001 for KO, LSD post hoc test).  However, there was no difference in acute cocaine-
induced locomotor activity in KO mice compared to WT on day 1 (P>0.05, LSD post hoc 
test).  Chronic “binge” cocaine administration resulted in a significant higher locomotor 
activity on day 2 through to day 14 compared to day 1 in both WT (P<0.0001, LSD post hoc 
test) and KO (P<0.0001 LSD post hoc test) animals, demonstrating the development of 
sensitization (Fig 1A-D).  The cocaine-induced locomotor activity of KO mice on day 2 
through to day 14 was significantly higher compared to WT (P<0.05, LSD post hoc test), 
indicating an enhancement of cocaine-induced locomotor sensitization in KO mice after the 
second day of testing (day 2) (Fig. 1A-D).  There was no difference in locomotor activity in 
saline treated KO mice compared to WT on none of the 14 days of the study (P>0.05, LSD 
post hoc test). 
 
Influence of ppDYN deletion on cocaine-induced stereotypy behaviour 
 
 12
Stereotypy activity of WT and KO mice was scored 20 min after the second injection of saline 
or cocaine every day for the whole duration of the study (Fig. 2).  Three-way ANOVA, 
genotype (WT, KO), treatment (saline, cocaine), day (day1-day14) with repeated measures on 
the last variable, showed a significant main effect of treatment [F(1,12)=1045.5, P<0.0001] and 
day [F(13,156)=4.78, P<0.0001] with no significant genotype effect (P=0.41).  LSD post hoc 
test showed that “binge” pattern cocaine administration resulted in a significant expression of 
behavioural stereotypy in both WT (P<0.0001) and KO (P<0.0001) animals compared to 
saline controls (Fig. 2).  However, there was no difference in cocaine-induced behavioural 
stereotypy in KO animals compared to WT (P=0.53).  Finally, there was no significant 
difference in stereotypy score in saline treated KO mice compared to WT (P=0.58).  The 
above results were confirmed with the use of non parametric Mann-Whitney U tests. 
 
Quantitative autoradiography of D1, D2 dopamine receptor and dopamine transporters  (DAT) 
in brains of chronic “binge” saline and cocaine treated WT and KO mice 
 
The qualitative and quantitative distribution of  D1, D2 dopamine receptor and DAT labelled 
with [3H]SCH-23390 (4 nM), [3H]raclopride (4 nM) and [3H]mazindol (4 nM) in coronal 
sections of brains of chronic “binge” saline treated mice was similar to previous studies from 
our group and others (Javitch et al. 1985; Puschban et al. 2000; Lena et al. 2004) (Fig. 3).  In 
the case of D2 dopamine receptor binding, two-way ANOVA for factors genotype and 
treatment, showed a significant genotype x treatment interaction [F(1,104)=6.9, P<0.01] with no 
significant main effect of genotype (P= 0.06) or treatment (P=0.12).  Lower overall D2 
dopamine receptor binding was observed in chronic “binge” cocaine treated KO mice 
compared to KO saline controls (P<0.01, LSD post hoc test)  and compared to cocaine treated 
WT (P<0.01, LSD post hoc test) (Fig. 4B).  Three-way ANOVA followed by post hoc LSD 
test showed significantly lower D2 dopamine receptor binding in the mediolateral part of the 
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caudate putamen of chronic “binge” cocaine treated KO mice compared to KO controls  
(P<0.05, LSD post hoc test) (Fig. 4B).  Although just the mediolateral part of the caudate of 
cocaine treated ppDYN KO mice showed a statistically significant (P<0.05) decrease in D2 
receptor binding, there was an 18-27 % decrease in D2 receptor binding in all the regions 
analysed.  In addition, D2 receptor binding difference between saline and cocaine ppDYN KO 
groups in the caudate putamen and the medial part of the caudate putamen were close to 
significance (P=0.06).  However, no significant difference in D2 dopamine receptor binding 
was observed in any of the regions of chronic cocaine treated WT mice compared to saline 
controls (P>0.05).  In contrast to D2 dopamine receptor binding, there was no significant 
genotype or treatment or treatment x genotype interaction effect of D1 dopamine receptor 
(Fig. 4A) and DAT (Fig. 4C) binding (P>0.05). 
 
-opioid receptor stimulated [35S]GTPS binding autoradiography in brains of chronic 
“binge” saline and cocaine treated WT and ppDYN KO mice 
 
[35S]GTPS autoradiography was performed in coronal brain sections of chronic “binge” 
saline or cocaine treated WT and KO mice in order to investigate whether alterations in MOP-
r stimulated G protein activity after chronic “binge” cocaine administration are affected by the 
deletion of the ppDYN gene.  Representative sections are illustrated in Fig. 5 in which the 
basal [35S]GTPS binding, DAMGO (5 M) stimulated [35S]GTPS binding and non-specific 
binding (NSB) are shown in chronic “binge” saline and cocaine treated WT and ppDYN KO 
mice.  Two-way ANOVA for factors genotype and treatment, showed a significant main 
effect of genotype  [F(1,252)=8.52, P<0.01] and a significant genotype x treatment interaction 
[F(1,252)=47.46, P<0.05].  No significant treatment effect was observed (P=0.35).  Chronically 
saline treated KO mice showed higher MOP-r  stimulated [35S]GTPS binding compared to 
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wild type controls (P<0.001, LSD post hoc test) (Fig. 6).  There was higher averall MOP-r 
stimulated [35S]GTPS binding  in cocaine treated WT mice brains compared to saline 
controls (P<0.05, LSD post hoc test).  However, there was no difference in MOP-r stimulated 
[35S]GTPS binding  in cocaine treated KO brains compared to saline controls (P=0.47, LSD 
post hoc test) (Fig. 6). 
 
Influence of ppDYN deletion on chronic “binge” cocaine-induced increase of plasma 
corticosterone levels 
 
Two-way ANOVA for factors genotype and treatment showed no significant genotype or 
treatment effect or genotype x treatment interaction effect (P>0.05).  As identical chronic 
“binge” cocaine treatment paradigm has been shown to increase corticosterone levels in mice 
and rats (Zhou et al. 1999; Schlussman et al. 2003), we carried out post hoc tests to 
investigate the effect of cocaine on corticosterone levels in WT and KO mice separately.  
Chronic “binge” cocaine administration increased plasma corticosterone levels significantly 
in WT animals (P<0.05, LSD post hoc test) but not in KO animals (P=0.84) (Fig. 7).  There 
was no significant difference between corticosterone levels of chronic “binge” cocaine treated 
WT mice compared to chronic “binge” cocaine treated KO mice (Fig. 7).  
 
Discussion 
 
The behavioural results obtained in this study show an enhanced cocaine-induced locomotor 
sensitization in ppDYN KO mice after a chronic “binge” administration protocol, but a lack 
of genotype effect in the acute locomotor response to cocaine.  This lack of genotype effect 
after acute cocaine (15 mg/kg) injection contrasts with previous data regarding the role of the 
endogenous KOP-r systems in regulating locomotor responses to acute cocaine 
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administration.  For example, KOP-r agonists have been repeatedly shown to decrease acute 
cocaine-induced locomotor activity (Crawford et al. 1995; Zhang et al. 2004b).  In addition, 
mice lacking the KOP-r were shown to have increased locomotor response to acute cocaine 
administration compared to WT (Chefer et al. 2005).  Interestingly, a decrease in acute 
cocaine-induced locomotor activity in ppDYN KO mice was recently reported (Chefer and 
Shippenberg 2006).  The discrepancy between our study and Chefer and Shippenberg (2006) 
could be due to the different experimental protocols used in these two studies or to the 
different derivation of the ppDYN deletion.  Compensatory changes occurring in ppDYN KO 
mice could account for the lack of the expected increase in acute cocaine-induced locomotor 
activity in ppDYN KO mice.  Previous study from our lab showed a marked compensatory 
upregulation of KOP-r in the brain of ppDYN KO mice (Clarke et al. 2003), suggesting that 
in the absence of dynorphin, endogenous -endorphin, which has been shown to be increased 
in the nucleus accumbens after acute cocaine injection (Olive et al. 2001) might activate the 
KOP-r resulting in decreased locomotion (Chefer and Shippenberg 2006).   
 
The enhancement of cocaine-induced locomotor sensitization in ppDYN KO mice is in 
agreement with previous studies which show that KOP-r agonists including dynorphin A1-13 
attenuates the development cocaine-induced locomotor sensitization (Heidbreder et al. 1993; 
Heidbreder et al. 1995; Shippenberg and Rea 1997).  Given that repeated cocaine 
administration increases striatal ppDYN levels (Spangler et al. 1993; Turchan et al. 1998; 
Werme et al. 2000), the results from our study suggests that the chronic “binge” cocaine-
induced activation of the KOPsystem opposes the behavioural responses to cocaine that 
develops after repeated use, possibly by inhibiting dopamine release (Shippenberg et al. 2001; 
Kreek et al. 2002). 
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Interestingly, in contrast to locomotor activity, both WT and ppDYN KO mice lack any kind 
of sensitisation effect of cocaine on stereotypy behaviour.  This is in complete accordance 
with studies showing a lack of increase of cocaine-induced stereotypy in rodents, during an 
identical 14 day chronic “binge” cocaine administration paradigm (Schlussman et al. 2003; 
Schlussman et al. 2005).  As in the above studies and ours, stereotypy was recorded in the 
home cage, it is possible that repeated cocaine does not produce sensitization of the  
behavioural stereotypy when cocaine is administered in the home cage. 
 
Our study also gives direct evidence that ppDYN mediates neurochemical changes occurring 
in the MOP system following chronic “binge” cocaine administration.  The increase in MOP-r 
stimulated [35S]GTPS binding in the brains of WT chronic “binge” cocaine administered 
mice accords with Schroeder et al. (2003) who showed an upregulation of MOP-r stimulated 
G protein activity in the rat after an identical treatment paradigm in this species, and others 
have shown an upregulation of the MOP-r system after chronic cocaine treatment (Unterwald 
et al. 1992; Unterwald et al. 1994a; Zubieta et al. 1996; Unterwald 2001; Bailey et al. 2005a).  
We have previously shown that MOP-r are upregulated in the absence of the ppDYN gene 
(Clarke et al. 2003).  The increased MOP-r stimulated [35S]GTPS binding in the brains of  
chronic “binge” saline treated KO mice indicates that the compensatory changes do not only 
occur at the receptor level but also at other components of the MOP-r signalling pathway.  In 
contrast to WT mice, there was no change in MOP-r stimulated G protein activity in ppDYN 
KO mice following chronic cocaine treatment suggesting that ppDYN may mediate chronic 
“binge” cocaine-induced alterations in MOP-r activity.  This suggestion is in complete 
agreement with Narita et al. (2003) who showed an upregulation in MOP-r stimulated  
[35S]GTPS binding in brains of mice chronically treated with KOP-r receptor agonist.  
However, it should be noted that the lack of increase in MOP-r stimulated [35S]GTPS 
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binding following chronic “binge” cocaine treatment in KO mice might also be due to 
differences in the baseline responses in these mice rather than due to the cocaine responses.  
Our study is the first to show direct in vivo evidence for the role of the endogenous KOP 
system in mediating chronic cocaine-induced neuromolecular alterations. 
 
It is unlikely that the lack of cocaine-induced increase in MOP-r activity in ppDYN KO mice 
would affect cocaine-induced locomotor sensitization, as recent studies suggest that MOP-r 
are not required neither for acute locomotor response to cocaine nor are they essential for the 
development of cocaine-induced behavioural sensitization (Hummel et al. 2004; Lesscher et 
al. 2005).  Indeed, no change in behavioural sensitization to cocaine was observed between 
WT and MOP-r KO mice (Lesscher et al. 2005).  However, the lack of MOP-r activation in 
ppDYN KO mice might influence other behaviours related to cocaine abuse such as cocaine-
induced conditioned place preference and self-administration.  In support of this, systemic 
administration of opioid antagonists have consistently been shown to decrease cocaine-
induced conditioned place preference (Houdi et al. 1989; Gerrits et al. 1995; Kuzmin et al. 
1997a), depresse cocaine self-administration, and delay cocaine initiation on the following 
day (Kiyatkin and Brown 2003). 
 
In contrast to the MOP-r system, the D2 dopaminergic system was not shown to be altered 
following chronic “binge” cocaine treatment in WT animals.  The lack of significant decrease 
in D2 receptor binding observed in the brains of chronic “binge” cocaine treated WT animals 
compared to saline is in contrast with the consistent report of a decrease in D2 receptor 
binding and availability following chronic cocaine exposure in rodents, primates and abstinent 
humans (Goeders and Kuhar 1987; Kleven et al. 1990; Peris et al. 1990; Volkow et al. 1990; 
Zeigler et al. 1991; Alburges et al. 1993; Volkow et al. 1993; Laurier et al. 1994; Tsukada et 
al. 1996; Maggos et al. 1998).  However, our study is in agreement with a study performed by 
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Unterwald et al. (1994b) who showed a lack of alteration in D2 receptor binding in rats treated 
with cocaine under the same experimental protocol that we used.  Thus, one has to consider 
the discrepancy in experimental paradigms as well as ligands used between studies.  In 
contrast to WT animal, there was a significant decrease in D2 receptor binding in the brains of 
chronic cocaine treated ppDYN KO mice compared to saline controls and compared to 
cocaine treated WT animals.  These findings further endorse studies showing strong 
interactions between the KOP-r system and the D2 dopaminergic system.  The inhibitory 
action of KOP-r agonists on extracellular dopamine levels in the striatum (Di-Chiara and 
Imperato 1988; Spanagel et al. 1992) suggests a close functional interaction between the 
KOP-r system and the D2 receptor dopaminergic system.  The exact mechanism for the 
downregulation of D2 receptors in chronic cocaine treated ppDYN KO mice as well as the 
nature of the population of those receptors (i.e. pre- or prost- synaptic) cannot be determined 
from this experiment.  However, there is evidence that  D2 autoreceptors are crucial in 
controlling extracellular dopamine induced by cocaine (Rosin et al. 1999).  The alterations in 
D2 receptor binding in ppDYN KO mice might partially explain the enhancement of cocaine-
induced sensitization in these animals.  Although the changes in D2 dopamine receptor 
binding are relatively small (18-27 %) that does not rule out the possibility that they might be 
of behavioural significance.  For instance small changes in opioid receptor density (20-30 %) 
in A2A adenosine receptor KO mice have been shown to result in marked changes in 
antinociceptive responses (Bailey et al. 2002).  Behavioural sensitization to cocaine has been 
previously attributed to changes in presynaptic D2 receptor function (King et al. 1994; Jones 
et al. 1996).  Moreover, activation of presynaptic D2 receptors has been shown to decrease 
extracellular dopamine levels by means of inhibition of dopamine synthesis and release 
(Dwoskin and Zahniser 1986; Zetterstrom et al. 1986).  Taken together, these results suggest 
that the enhancement of cocaine sensitization in chronic cocaine treated ppDYN KO mice 
might partly be due to the downregulation of presynaptic D2 receptor in these animals.  This 
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finding suggests that ppDYN not only opposes the alteration in locomotion but also may 
oppose alterations in D2 receptor binding resulting from chronic cocaine use.   
 
Although anatomical and neurochemical data suggest the existence of an interaction between 
the KOP-r system and the D1 receptor as well as with the DAT (Izenwasser et al. 1998; 
Thompson et al. 2000; Collins et al. 2001a), no change in either D1 receptor or DAT binding 
was observed either in cocaine-treated animals or in mice lacking the ppDYN gene.  There is 
literature that has shown a lack of change in D1 receptor number and affinity and in dopamine 
uptake in rats repeatedly treated with the KOP-r agonist U-69593 (Izenwasser et al. 1998).  
As for DAT binding, as assessed by radioligand binding, the number of DAT binding sites 
has been reported to increase (Alburges et al. 1993; Little et al. 1993; Staley et al. 1994; 
Wilson et al. 1994b; Hitri et al. 1996; Little et al. 1998; Little et al. 1999) or decrease (Sharpe 
et al. 1991; Farfel et al. 1992; Hurd and Herkenham 1993; Pilotte et al. 1994; Wilson et al. 
1994b; Pilotte et al. 1996), whereas in other studies the number of DAT sites remains 
unchanged (Allard et al. 1990; Kula and Baldessarini 1991; Sharpe et al. 1991; Benmansour 
et al. 1992; Cass et al. 1993; Pilotte et al. 1994; Wilson et al. 1994a; Kunko et al. 1997) in 
reponce to cocaine treatment.  The lack of accordance in these results may arise from 
differences in treatment paradigms (varying dosage, schedule and route of administration), 
length of withdrawal, and/or ligand used to quantify DAT.  A study conducted by Maggos et 
al. (1997) in rats, who used an identical chronic “binge” cocaine administration protocol to 
our study, failed to demonstrate an alteration in DAT mRNA in the cocaine group.  The 
present study suggest that the increase in ppDYN after chronic “binge” cocaine administration 
is not involved in any alteration in D1 receptor or DAT expression.  However, that does not 
exclude the possibility that DAT function (e.g. increases or decreases in dopamine uptake or 
release) is altered in the brains of saline or chronically “binge” cocaine treated ppDYN KO 
mice.  It has been suggested that treatment with KOP-r agonists may lead to post-translational 
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modification of DAT and as a result, lower extracellular dopamine levels by increasing the 
rate of dopamine uptake or  decreasing dopamine release or both (Thompson et al. 2000).   
 
Finally, while in WT mice an increase in corticosterone levels and thus an activation of the 
HPA axis in response to chronic “binge” cocaine treatment was observed, in KO animals this 
activation was blunted, which suggests that cocaine-induced stimulation of the HPA axis may 
be mediated by ppDYN.  These results are of  significant interest given that the KOP-r system 
has been implicated in mediating stress-induced behavioural responses leading to detrimental 
behaviours such as drug abuse (Przewlocki et al. 1987; Nabeshima et al. 1992; Watanabe et 
al. 1995; Mello and Mendelson 1997; Carlezon et al. 1998; Kreek and Koob 1998; 
McLaughlin et al. 2003).   Although the mechanism mediating stress-induced enhancement of 
rewarding properties of drugs of abuse as well as self-administration are not clear, one 
possible mechanism has been proposed to involve stress-induced activation of the HPA axis 
which subsequently activates the endogenous KOP-r system (Przewlocki et al. 1987; 
Nabeshima et al. 1992; Watanabe et al. 1995) presumably thereby modulating drug reward 
and self-administration (Mello and Mendelson 1997; Carlezon et al. 1998; Kreek and Koob 
1998).  Indeed, recent evidence strongly suggests that stress activates the KOP system and 
that  -opioid antagonism and ppDYN gene disruption block stress-induced behaviours and 
stress-induced behavioural responses to cocaine (McLaughlin et al. 2003).  The lack of 
cocaine-induced increase in corticosterone levels in ppDYN KO mice which represents a lack 
of cocaine-induced activation of the HPA axis is in complete accordance with the literature 
suggesting that cocaine-induced stimulation of the HPA axis is mediated by the endogenous 
KOP-r system and more specifically by ppDYN.  One cannot draw conclusions as to whether 
the above effect on the HPA axis observed in KO mice affects the cocaine-induced locomotor 
sensitisation behaviour as described in this paper as it is unclear how HPA axis activity 
affects locomotion.  However, McLaughlin et al., (2003) demonstrated that ppDYN KO mice 
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subjected to repeated stress (forced swim test) showed significantly reduced preference to 
cocaine as measured with CPP compared to WT.  
 
In conclusion, the present study demonstrates that ppDYN may play a central role not only in 
mediating the behavioural effects of cocaine but also in mediating the neuromolecular effect 
of cocaine on the D2 dopaminergic and the MOP-r system as well as mediating the effects of 
cocaine on the HPA axis, providing further evidence that the ppDYN system functions as an 
endogenous antagonist of cocaine.  Although additional studies are needed to elucidate further 
mechanisms underlying the effect of KOP-r modulation of drug addiction, the present 
behavioural and neurochemical data prompt further investigation of the effectiveness of KOP-
r agonists as a novel pharmacotherapeutic compound in the treatment of cocaine addiction.  
Although it has been previously reported that treatment with selective KOP-r agonists cause 
psychotomimetic effects and dysphoria in clinical trials (Wadenberg 2003), synthesis of novel 
KOP-r agonists such as TRK-820 which lacks any aversive effects may be useful for the 
treatment of cocaine addiction. 
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Legend to Figure 1.  Representative graphs of locomotor activity in wild type (WT) and 
ppDYN knockout (KO) mice after an injection of saline or cocaine during a chronic “binge” 
administration paradigm.  The locomotor data were collected daily in 5 min bins following 
the first of the three injections of a “binge” pattern cocaine (15 mg/kg) or saline.  For brevity, 
responses are shown on day 1 (Fig. 1A) and days 3, 7 and 14 (Fig. 1B-D).  Values are mean ± 
S.E.M of 6 animals in each group.  Cocaine significantly increased locomotor activity in WT 
and KO mice on days 1, 3, 7 and 14 (P<0.0001).  Cocaine- induced locomotion was increased 
on day 3, 7 and 14 compared to day 1 in both WT and KO mice (P<0.001).  Cocaine-induced 
locomotion was higher in KO mice compared to WT on days 3, 7 and 14 (P<0.05). 
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***P<0.001 vs Cocaine WT on the same day; **P<0.01 vs Cocaine WT on the same day; 
*P<0.05 vs Cocaine WT on the same day 
 
Legend to Figure 2.  Daily stereotypy scores in wild type (WT) and ppDYN knockout (KO) 
mice following chronic “binge” cocaine treatment.  The stereotypy score assigned to each 
animal was based on its behaviour 20 min after the second of the three injections of “binge” 
pattern cocaine or saline administration.  Values are mean ± S.E.M of 6 animals in each 
group.  Chronic “binge” pattern cocaine administration significantly increased levels of 
behavioural stereotypy in WT and KO mice (P<0.0001).  There was no statistically 
significant genotype difference in saline or cocaine treated animals (P>0.05). 
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Legend to Figure 3.  Computer-enhanced autoradiograms of coronal brain sections from 
chronically “binge” saline and cocaine treated wild-type (WT) and ppDYN knockout (KO) 
mice.  The adjacent sections shown are from the level of the caudate (Bregma 1.00mm).  D1, 
D2 dopamine receptor and dopamine transporters (DAT) were labelled with [3H]SCH-23390 
(4 nM), [3H]raclopride (4 nM) and [3H]mazindol (4 nM) respectively.  The colour bar 
represents a pseudo-colour interpretation of  black and white film images in fmol mg-1 tissue 
equivalent.  Sections cut from chronically “binge” saline and cocaine treated WT and KO 
mice brains were processed in parallel. 
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Legend to Figure 4.  Quantitative autoradiography  of  D1, D2 dopamine receptor and 
dopamine transporters binding in coronal brain sections from chronically “binge” saline and 
cocaine treated wild-type (WT) and ppDYN knockout (KO) mice.  Data are expressed as the 
mean specific binding (fmol/mg)  ± S.E.M of 5 determinants (n=5) of A) [3H]SCH-23390, B) 
[3H]raclopride and C)  [3H]mazindol  in brain regions of  chronically “binge” saline and 
cocaine treated WT and ppDYN KO mice.  Regional determinations were made from both 
left and right sides of the sections.  The labelling was carried out on sections from chronically 
“binge” saline and cocaine treated WT and ppDYN KO mice in a completely paired protocol. 
Specific binding was >80 % in all regions analysed.  There was a significant genotype x 
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treatment interaction (ANOVA) for [3H]raclopride binding  but not for [3H]SCH-23390 and 
[3H]mazindol binding.    * P<0.05 vs saline KO; (LSD post hoc test).  Abbreviations:  PrLCx, 
Prelimbic cortex; CgCx, Cingulate cortex; MCx, Motor cortex; AcbC, Nucleus accumbens 
core; AcbSh, Nucleus accumbens shell; Tu, Olafactory tubercle; Den, Dorsal endopiriform; 
Cl, Claustrum; CPu, Caudate putamen; CPuM, Medial part of CPu; CPuL, Mediolateral part 
of CPu; Sept, Septum; Th, Thalamus; Hy, Hypothalamus; Hip, Hippocampus; Amy, 
Amygdala; SN, Substantia nigra; SuG, Superficial gray layer of the superior colliculus; 
AuCx, Auditory cortex; ViCx, Visual cortex; STh, Subthalamic nucleus 
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Legend to Figure 5.  Computer-enhanced autoradiograms of coronal brain sections from 
chronically “binge” saline and cocaine treated wild-type (WT) and ppDYN knockout (KO) 
mice.  The sections shown are A) from the level of the caudate (Bregma 1.00mm) and B) 
from the level of the hippocampus (Bregma –2.56 mm).   Sections were preincubated with 1 
mM GDP and then incubated for 2 h with [35S]GTPS (0.04 nM) and 1 mM GDP (basal), 
[35S]GTPS (0.04 nM) and 1 mM GDP in the presence of DAMGO (5 M) (MOP-r 
stimulated [35S]GTPS) or with [35S]GTPS (0.04 nM) and 1 mM GDP in the presence of 
10M unlabelled GTPS (non-specific binding).  The colour bar represents a pseudo-colour 
interpretation of relative black and white film images.   Sections cut from chronically “binge” 
saline and cocaine treated WT and KO mice brains were processed in parallel. 
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Legend to Figure 6.  DAMGO stimulated [35S]GTPS binding in coronal brain sections from 
chronically “binge” saline and cocaine treated wild-type (WT) and ppDYN knockout (KO) 
mice.  Data are expressed as mean ± S.E.M (n=6).  There was a significant genotype (P<0.01) 
and a significant genotype x treatment interaction (P<0.05).  No significant treatment effect 
was observed (P=0.35).  Chronically saline treated KO mice showed an increase in MOP-r  
stimulated [35S]GTPS binding compared to WT (P<0.001).  Chronic “binge” cocaine 
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administration increased MOP-r stimulated [35S]GTPS binding in WT mice (P<0.05) but not 
in KO (P=0.47).  Abbreviations:  MCx, motor cortex; CgCx,  cingulate cortex; AcbC, 
accumbens core; AcbSh, accumbens shell; CPu, caudate putamen; Th, thalamus; Hy, 
hypothalamus; Amy, amygdala.  
 
Legend to Figure 7.  Effect of chronic “binge” cocaine administration on plasma 
corticosterone levels of wild type (WT) and ppDYN knockout (KO) mice.  Data are expressed 
as mean ± S.E.M (n=6).  Chronic “binge” cocaine administration increased plasma 
corticosterone levels significantly in WT animals (P<0.05, LSD post hoc test) but not in KO 
animals (P=0.84).  There was no significant difference between corticosterone levels of 
chronic “binge” cocaine treated WT mice compared to chronic “binge” cocaine treated KO 
mice.  * P<0.05 vs WT saline  
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